Table 3.

Clinical outcomes in 347 HT recipients during the first 3 years after HT surgery by 2 post-HT weight groups^a: Group 1 = non-overweight; Group 2 = overweight.

Outcome	Group 1 (N = 108)	Group 2 (N = 239)	χ2b	Fc	Pd
CAV	5.6%	18.0%	14.84		.002
Stroke	10.2%	5.4%	2.91		.088
Severe renal dysfunctione	18.5%	13.4%	6.76		.009
New-onset steroid-induced diabetes	10.2%	14.2%	5.11		.024
Lymphoma	7.4%	1.7%	7.64		.006
Number of days re-hospitalized after HT discharge	36 ± 44	33 ± 36		3.37	.010
Number of treated acute rejections	3.1 ± 3.1	3.7 ± 3.6		4.00	.003
Number of IV-treated infections	2.3 ± 2.9	1.9 ± 2.5		1.68	.155

CAV, cardiac allograft vasculopathy; HT, heart transplant; IV, intravenous.

^aWeight groups based on mean post-transplant BMI (body mass index = kg/m²): Group 1 (non-overweight) = BMI <25 (range = 16–24, mean = 22, SD = 1.9); Group 2 (overweight) = BMI ≥ 25 (range = 25–40, mean = 29, SD = 3.2).

^bLogistic regression (χ²) was used for dichotomous outcomes (%) and adjusted for covariates of patient gender, patient age at HT, and donor age.

^cMANCOVA (F) was used for continuous outcomes (mean ± standard deviation) and adjusted for covariates of patient gender, patient age at HT, and donor age.

^dSignificance determined at P ≤ .025.

^eDefined as a serum creatinine >2.5 mg/dl or a diagnosis of renal failure or on dialysis.⁹